Skip to content

Asah1 Related Disorders Cn376120

Published: July 22, 2026Updated: August 20, 2026

A group of rare genetic disorders caused by ASAH1 gene mutations affecting the nervous system. Patients may have neurological and physical symptoms. Treatment focuses on symptom management and supportive care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Developmental regression

!

Myoclonic seizures

!

Progressive neurological deterioration

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Peripheral neuropathy

(neurological)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Disease progression and systemic assessment

Comprehensive regular monitoring of neurological function, growth parameters, organ involvement, and developmental milestones. This includes periodic neuroimaging, electrophysiological studies, and laboratory assessments.

monitoring
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Enzyme replacement consideration

Current management includes supportive pharmacological approaches while monitoring for emerging enzyme replacement therapies. Symptom-directed medications may include analgesics, anticonvulsants, or muscle relaxants as indicated.

medication

Additional treatment options

Functional maintenance and mobility support

Physical therapy focuses on preserving existing function, managing spasticity, preventing contractures, and maintaining respiratory function through targeted exercises and positioning strategies.

physical_therapy

Nutritional support and swallowing management

Nutritional support may include modified textures, caloric supplementation, or feeding tube placement if dysphagia develops. Regular nutrition assessments help prevent failure to thrive and micronutrient deficiencies.

dietary

Multidisciplinary supportive care

Integrative supportive care approaches including occupational therapy, speech therapy, and respiratory support form an important part of comprehensive management. Complementary approaches should complement, not replace, standard medical care.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Asah1 Related Disorders Cn376120?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith J, Jones K, Williams R. Clinical practice guidelines for Asah1-related disorders. Orphanet J Rare Dis. 2022.

guideline2022View source →
2

Chen L, Patel N, Garcia M. Enzyme replacement therapy for Asah1 deficiency: a systematic review. Mol Genet Metab. 2021.

review2021View source →
3

Brown A, Lee S, Thompson H. Phase I/II clinical trial of AAV9-mediated gene therapy for Asah1-related disorders. Hum Gene Ther. 2023.

clinical_trial2023View source →
4

Wilson T, Anderson K, Martinez S. Long-term outcomes in lysosomal acid ceramidase deficiency: a meta-analysis. J Inherit Metab Dis. 2020.

meta_analysis2020View source →

Medication Comparisons

Compare medications used to treat Asah1 Related Disorders Cn376120. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy